Skip to main content

REVIEW article

Front. Mar. Sci.
Sec. Marine Biotechnology and Bioproducts
Volume 11 - 2024 | doi: 10.3389/fmars.2024.1523246

Marine Natural Products as an Important Source of Bioactive Substances for Non-Alcoholic Fatty Liver Disease Management

Provisionally accepted
Menglei Shi Menglei Shi 1,2Sisi Chen Sisi Chen 2,3Yutong Feng Yutong Feng 2,4Shiyuan Wang Shiyuan Wang 2Yuyu Xia Yuyu Xia 2Jianlin He Jianlin He 2*
  • 1 School of Advanced Manufacturing, Fuzhou University, Quanzhou, Fujian Province, China
  • 2 Technology Innovation Center for Exploitation of Marine Biological Resources, Third Institute of Oceanography, Ministry of Natural Resources, Xiamen, Fujian Province, China
  • 3 School of Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning Province, China
  • 4 School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, Liaoning Province, China

The final, formatted version of the article will be published soon.

    With an estimated global prevalence of 32.4%, non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent chronic liver condition. The marine ecosystem, distinguished by its distinctive environmental characteristics, is a treasure trove of novel lead compounds possessing unique chemical structures, offering promising avenues for the development of new therapeutic agents or dietary supplement targeting NAFLD. Marine bioactive substances from natural products, such as polysaccharides, polyphenols, polyunsaturated fatty acids, and peptides, have been shown to benefit liver health by alleviating metabolic dysfunction through multiple mechanisms. This paper reviews the effects of marine bioactive substances from various marine entities, including marine fauna, flora, and microorganisms, on the regulation of NAFLD. A brief overview of the predominant pathogenic mechanisms underlying the disease is also provided, thereby establishing a critical link between the therapeutic potential of marine bioactive substances and the management of NAFLD.

    Keywords: metabolic disorders, chronic liver disease, Lipids, lead compounds, Dietary Supplements

    Received: 05 Nov 2024; Accepted: 31 Dec 2024.

    Copyright: © 2024 Shi, Chen, Feng, Wang, Xia and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jianlin He, Technology Innovation Center for Exploitation of Marine Biological Resources, Third Institute of Oceanography, Ministry of Natural Resources, Xiamen, Fujian Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.